TRIFED price in UAE

Overview

Welcome to Dwaey, specifically on TRIFED Tablets page.
This medicine contains an important and useful components, as it consists of Pseudoephedrine HCl, Triprolidine HCl.
TRIFED is available in the market in concentration 60mg, 2.5mgTablet and in the form of Tablets.

AL HIKMA PHARMACEUTICALS is the producer of TRIFED and it is imported from JORDAN, The most popular alternatives of TRIFED are listed downward .

Mode Of Action

Triprolidine hydrochloride is a potent competitive histamine H1-receptor antagonist with antimuscarinic and mild sedative properties. Pseudoephedrine, an alpha- and beta-adrenergic receptor agonist, mediates vasoconstriction via direct stimulation of alpha-adrenergic receptors of the respiratory mucosa.

Indication

Pneumonia
Pharyngitis
Allergic rhinitis
Upper respiratory tract
Dry cough
Tracheolaryngitis

Precaution

Severe hepatic impairment. Moderate to severe renal impairment. DM, hyperthyroidism, increased intraocular pressure, prostatic hypertrophy, hypertension, heart disease. May affect ability to drive or operate machinery. Pregnancy and lactation.

Side Effects

Dry mouth
nose and throat; skin rashes
tachycardia
drowsiness
sleep disturbances
urinary retention. Rarely
hallucinations.

Contra indication

Concurrent use or within 2 wk of stopping MAOIs. Severe hypertension or coronary artery disease.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

Increased BP with other sympathomimetic agents (e.g. decongestants, TCA, appetite suppressants). Reduced hypotensive effects of methyldopa, ?- and ?-adrenergic blockers. Increased side effects (e.g. somnolence, agitation) with atomoxetine. Potentially Fatal: Increased risk of hypertensive crisis with furazolidine, avoid concurrent use. Increased risk of hypertensive crisis with MAOIs; avoid concurrent use or within 2 wk after stopping MAOIs. Increased risk of psychosis with bromocriptine.